[{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Coagulation Factor X","moa":"Coagulation factor X||Factor Xa","graph1":"Hematology","graph2":"Approved FDF","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Factor X","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase III","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Factor X","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase III","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Coagulation Factor VIII","moa":"F8*","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Factor IX","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Factor IX","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Factor IX","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Factor IX","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Factor IX","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Gammaplex","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Gammaplex","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Human Normal Immunoglobulin","moa":"High affinity immunoglobulin gamma Fc receptor I; Putative high affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Human Normal Immunoglobulin","moa":"High affinity immunoglobulin gamma Fc receptor I; Putative high affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Human Normal Immunoglobulin","moa":"High affinity immunoglobulin gamma Fc receptor I; Putative high affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Human Anti-D Immunoglobulin","moa":"Rhesus blood group D antigen","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"HRIG","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Bio Products Laboratory","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Immunoglobulin","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Products Laboratory \/ Bio Products Laboratory","highestDevelopmentStatusID":"11","companyTruncated":"Bio Products Laboratory \/ Bio Products Laboratory"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"CSI Pharmacy","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Agreement","leadProduct":"Human Immunoglobulin","moa":"Fc receptor||Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Products Laboratory \/ Bio Products Laboratory","highestDevelopmentStatusID":"15","companyTruncated":"Bio Products Laboratory \/ Bio Products Laboratory"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Optivate Human Coagulation Factor VIII","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Optivate Human Coagulation Factor VIII","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Optivate Human Coagulation Factor VIII","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Optivate Human Coagulation Factor VIII","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Optivate Human Coagulation Factor VIII","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Subgam","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio Products Laboratory \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Bio Products Laboratory
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
